The news: Robert F. Kennedy Jr.’s nomination as the head of the Department of Health and Human Services has some pharmaceutical companies worried that the incoming Trump administration could significantly restrict the industry’s ability to advertise to consumers.
The impact: Healthcare and pharmaceutical advertisements account for $22.09 billion (7.3%) of the $310.19 billion in US digital ad spending, per our forecast. Healthcare and pharmaceutical companies are frequent TV advertisers, and a D2C ad ban could deal a blow to networks’ advertising revenues.
Will it actually happen? As with many proposals made by incoming Trump administration officials, it’s unclear. Kennedy has taken a hard stance against several pharmaceutical and fast food industry practices, but the big-business friendly Trump administration and limited support in Congress could hinder those efforts.
Our take: The Trump administration’s big business-friendly agenda lessens the likelihood that Kennedy would be able to impose such restrictions should he be confirmed.
This article is part of EMARKETER’s client-only subscription Briefings—daily newsletters authored by industry analysts who are experts in marketing, advertising, media, and tech trends. To help you finish 2024 strong and start 2025 off on the right foot, articles like this one—delivering the latest news and insights—are completely free through January 31, 2025. If you want to learn how to get insights like these delivered to your inbox every day and get access to our data-driven forecasts, reports, and industry benchmarks, schedule a demo with our sales team.